Condition (MeSH)
Corneal Endothelial Cell Loss
ClinicalTrials.gov lists 28 trials for Corneal Endothelial Cell Loss or a narrower condition beneath it. Topcon Medical Systems, Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
28 of the 28 trials are tagged with Corneal Endothelial Cell Loss itself; the rest are tagged with a narrower condition beneath it.
When did Corneal Endothelial Cell Loss trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Corneal Endothelial Cell Loss trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 10 |
| Observational | 10 |
How many Corneal Endothelial Cell Loss trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Completed | 14 |
| Terminated | 1 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Corneal Endothelial Cell Loss trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Topcon Medical Systems, Inc. | 2 |
| Biogen | 1 |
| Caravel Oculus Pty Ltd | 1 |
| Emmecell | 1 |
Which drugs are being tested for Corneal Endothelial Cell Loss? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Vitamin C | 1 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Omaveloxolone Ophthalmic Suspension 1% | 1 |
| Ophthalmic solution (matching formulation without ascorbic acid) | 1 |
| Lumason® contrast agent | 1 |
| 500K cells | 1 |
| Ascorbic acid ophthalmic solution 5% | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Corneal Endothelial Cell Loss trials report? (8)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cerebrovascular accident | 1 | 1 |
| Diverticulum | 1 | 1 |
| Gastrointestinal haemorrhage | 1 | 1 |
| Haemorrhagic cerebral infarction | 1 | 1 |
| Intraocular pressure increased | 1 | 1 |
Showing 5 of 8 adverse events.
Which publications cover Corneal Endothelial Cell Loss? (64)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study: A Randomized Clinical Trial. | JAMA ophthalmology | 2025 | Yes |
| Preoperative and perioperative factors that predict endothelial cell loss 1 year after uncomplicated Descemet membrane endothelial keratoplasty. | PloS one | 2025 | Yes |
| Ascorbic acid ameliorates corneal endothelial dysfunction and enhances cell proliferation via the noncanonical GLUT1-ERK axis. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2021 | Yes |
| Corneal Endothelial Cell Density and Morphology After Phacoemulsification in Patients With Primary Open-Angle Glaucoma and Cataracts: 2-Year Results of a Randomized Multicenter Trial. | Cornea | 2019 | Yes |
| Comparison of effective phacoemulsification time and corneal endothelial cell loss using 2 ultrasound frequencies. | Journal of cataract and refractive surgery | 2019 | Yes |
Showing 5 of 64 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.